That analysis predated more recent critical studies involving anti-VEGF agents, such as Diabetic Retinopathy Clinical Research Network (DRCR) Protocol T, which demonstrated the superiority of aflibercept compared to bevacizumab and ranibizumab among eyes with DME and a baseline acuity worse than 20/40 [6], or Protocol S, or the CLARITY trial, which demonstrated the non-inferiority of anti-VEGF treatment (ranibizumab and aflibercept, respectively) compared to panretinal photocoagulation (PRP) in proliferative diabetic retinopathy [7,8]. The gene discussed is VEGFA; the disease is proliferative diabetic retinopathy.